Primary stroke Center Certification

CONTINUUM Lifelong Learning in Neurology

Volumn 14, Issue 6, 2008, Pages 98-116

  Levine, Steven R ^a   Adamowicz, David ^a   Johnston, Karen C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77349114393     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000275643.30322.f9     Document Type: Article

References (20)

1. Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA 2000;283(23):3102-3109.
2. Arora S, Broderick JP, Frankel M, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry [published erratum appears in Stroke, 2005,36(8):1820].
3. Stroke 2005;36(6): 1232-1240.
4. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006;63(5):661-664.
5. Burgin WS, Staub L, Chan W, et al. Acute stroke care in non-urban emergency departments. Neurology 2001;57(11):2006-2012.
6. Demaerschalk BM, Durocher DL. How diagnosis-related group 559 will change the US Medicare cost reimbursement ratio for stroke centers. Stroke 2007;38(4):1309-1312.
7. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005;36(11):2500-2503.
8. Fagan SC, Morgenstern LB, Pettita A, et al. Cost-effectiveness of tissue plasminogen activator for ischemic stroke. NINDS rt-PA. Stroke Study Group. Neurology 1998;50(4):883-900.
9. Gomez C. Time is brain. J Stroke Cerebrovasc Dis 1993;3:1-2. Joint Commission. Primary stroke center certification. www.jointcommission.org/ CertificationPrograms/PrimaryStrokeCenters/. Accessed: December 10, 2007.
10. Kidwell CS, Shephard T, Tonn S, et al. Establishment of primary stroke centers: a survey of physician attitudes and hospital resources. Neurology 2003;60(9): 1452-1456.
11. Kleindorfer D, Hill MD, Woo D, et al. A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke. Stroke 2005;36(3):682-687.
12. Kleindorfer D, Khoury J, Alwell K, et al. rt-PA use in a population-based study: the post-FDA approval era. Stroke 2003;34(1):283.
13. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004;35(2):e27-e29.
14. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340(23):1781-1787.
15. Lattimore SU, Chalela J, Davis L et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke 2003;34(6):55-57.
16. Mohammad YM, Divani AA, Jradi H, et al. Primary stroke center: basic components and recommendations. South Med J 2006;99(7):749-752.
17. Morrison K. The road to JCAHO disease-specific care certification: a step-by-step process log. Dimens Crit Care Nurs 2005;24(5):221-227.
18. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581-1587.
19. Saver JL. Time is brain-quantified. Stroke 2006;37(1):263-266.
20. Tilley BC, Lyden PD, Brott TG, et al. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol 1997;54(12):1466-1474.